Company Name: FibroGen, Inc.
FibroGen, Inc. is a biopharmaceutical company. The company is engaged in the development and commercialization of therapeutics utilizing fibrosis and hypoxia-inducible factor (HIF) biology. The company’s lead product candidate is a treatment for anemia in chronic kidney disease.
Ticker Symbol: FGEN (NASDAQ)
Company Website: www.fibrogen.com
Social Media: FibroGen LinkedIn
Headquarters: San Francisco, CA